vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and Phoenix Education Partners, Inc. (PXED). Click either name above to swap in a different company.
Phoenix Education Partners, Inc. is the larger business by last-quarter revenue ($222.5M vs $199.9M, roughly 1.1× Apellis Pharmaceuticals, Inc.). Phoenix Education Partners, Inc. runs the higher net margin — 4.8% vs -29.5%, a 34.3% gap on every dollar of revenue. Phoenix Education Partners, Inc. produced more free cash flow last quarter ($43.5M vs $-14.3M).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
The University of Phoenix (UoPX) is a private for-profit university headquartered in Phoenix, Arizona. Founded in 1976, the university confers certificates and degrees at the certificate, associate, bachelor's, master's, and doctoral degree levels. It is institutionally accredited by the Higher Learning Commission and has an open enrollment admissions policy for many undergraduate programs. The school is owned by Phoenix Education Partners.
APLS vs PXED — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $222.5M |
| Net Profit | $-59.0M | $10.8M |
| Gross Margin | — | — |
| Operating Margin | -25.6% | 6.3% |
| Net Margin | -29.5% | 4.8% |
| Revenue YoY | -5.9% | — |
| Net Profit YoY | -62.2% | — |
| EPS (diluted) | $-0.40 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $222.5M | ||
| Q4 25 | $199.9M | $262.0M | ||
| Q3 25 | $458.6M | — | ||
| Q2 25 | $178.5M | — | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | — | ||
| Q3 24 | $196.8M | — | ||
| Q2 24 | $199.7M | — |
| Q1 26 | — | $10.8M | ||
| Q4 25 | $-59.0M | $15.5M | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $-42.2M | — | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | — | ||
| Q2 24 | $-37.7M | — |
| Q1 26 | — | 6.3% | ||
| Q4 25 | -25.6% | 9.8% | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — |
| Q1 26 | — | 4.8% | ||
| Q4 25 | -29.5% | 5.9% | ||
| Q3 25 | 47.0% | — | ||
| Q2 25 | -23.6% | — | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | — | ||
| Q2 24 | -18.9% | — |
| Q1 26 | — | $0.28 | ||
| Q4 25 | $-0.40 | $0.40 | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | — | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $201.4M |
| Total DebtLower is stronger | — | $58.8M |
| Stockholders' EquityBook value | $370.1M | $291.1M |
| Total Assets | $1.1B | $546.4M |
| Debt / EquityLower = less leverage | — | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $201.4M | ||
| Q4 25 | $466.2M | $163.5M | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
| Q1 26 | — | $58.8M | ||
| Q4 25 | — | $61.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $291.1M | ||
| Q4 25 | $370.1M | $280.4M | ||
| Q3 25 | $401.2M | — | ||
| Q2 25 | $156.3M | — | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | — |
| Q1 26 | — | $546.4M | ||
| Q4 25 | $1.1B | $549.6M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $821.4M | — | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | — | ||
| Q3 24 | $901.9M | — | ||
| Q2 24 | $904.5M | — |
| Q1 26 | — | 0.20× | ||
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | $48.9M |
| Free Cash FlowOCF − Capex | $-14.3M | $43.5M |
| FCF MarginFCF / Revenue | -7.1% | 19.6% |
| Capex IntensityCapex / Revenue | 0.1% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 4.53× |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $48.9M | ||
| Q4 25 | $-14.2M | $31.1M | ||
| Q3 25 | $108.5M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | — | ||
| Q3 24 | $34.1M | — | ||
| Q2 24 | $-8.3M | — |
| Q1 26 | — | $43.5M | ||
| Q4 25 | $-14.3M | $26.4M | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
| Q1 26 | — | 19.6% | ||
| Q4 25 | -7.1% | 10.1% | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
| Q1 26 | — | 2.4% | ||
| Q4 25 | 0.1% | 1.8% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
| Q1 26 | — | 4.53× | ||
| Q4 25 | — | 2.01× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PXED
Segment breakdown not available.
